Intellipharmaceutics achieves net income of USD2.2m in Q1 2014
M2 - Tue Apr 15, 4:23AM CDT
Pharmaceutical company Intellipharmaceutics International (NasdaqCM:IPCI) (TSX:I) on Monday disclosed its net income of USD2.2m (USD0.09 per diluted common share) for the three months ended 28 February 2014.
Intellipharmaceutics Announces First Quarter 2014 Results
GlobeNewswire - Mon Apr 14, 6:01AM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 28, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014
GlobeNewswire - Wed Mar 19, 4:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has sent to registered shareholders an amended form of proxy for voting at its annual and special shareholders meeting to be held on March 27, 2014 (the "Meeting"
Correction - Mackie Research Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Mon Mar 17, 9:59AM CDT
Vancouver, BC, March 17, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.
Jennings Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Fri Mar 14, 5:22PM CDT
Vancouver, BC, March 14, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.
Intellipharmaceutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Mar 04, 4:00PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences.
Intellipharmaceutics posts higher net loss in 2013
M2 - Wed Feb 19, 6:11AM CST
Canadian pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Tuesday a net loss of USD11.5m (USD0.58 per common share) for the year ended 30 November 2013.
Intellipharmaceutics Announces 2013 Year End Results
GlobeNewswire - Tue Feb 18, 6:05AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2013. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Intellipharmaceutics International Inc awarded first profit-share of USD3.1m from Par Pharmaceuticals Inc for sales of 15 and 30 mg generic Focalin XR
M2 - Tue Feb 04, 4:33AM CST
Pharmaceutical company Intellipharmaceutics International Inc (TSX:I) said on Monday that it has received the first payment of USD3.1m relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its licensee Par Pharmaceutical Inc.
Intellipharmaceutics Receives $3.1 Million From Par Pharmaceuticals, Inc.
GlobeNewswire - Mon Feb 03, 6:00AM CST
- First Profit-Share Payment on 15 and 30 mg Generic Focalin XR(R) Sales
Intellipharmaceutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Mon Dec 02, 6:00AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief Financial Officer, will present a Company overview at the 25th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York at 1:00pm EST on Wednesday, December 4, 2013.
Intellipharmaceutics International Inc reports 'at-the-market offering' of 5.31m common shares
M2 - Thu Nov 28, 4:54AM CST
Pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Wednesday that it plans to sell up to 5,305,484 of its common shares through an 'at-the-market' offering programme.
Intellipharmaceutics Announces At-The-Market Offering of Common Shares
GlobeNewswire - Wed Nov 27, 3:30PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced an "at-the-market" offering program under which it may from time to time sell up to 5,305,484 of its common shares for up to an aggregate of US$16.8 million through at-the-market issuances on the NASDAQ Capital Market.
J.C. Penney, Lowe's, Tesla are big market movers
AP - Wed Nov 20, 3:55PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Ahead of the Bell: IntelliPharmaCeutics climbs
By The Associated Press - AP - Wed Nov 20, 7:38AM CST
Shares of IntelliPharmaCeutics International Inc. jumped again Wednesday before markets opened, as the generic drug developer continued a strong week that started with a key product approval.
IIROC Trade Resumption - I
CNW Group - Tue Nov 19, 7:32AM CST
Trading resumes in:
Intellipharmaceutics International Inc introduces 15 and 30 mg generic Focalin XR for attention deficit hyperactivity disorder in the market
M2 - Tue Nov 19, 5:34AM CST
Pharmaceutical company Intellipharmaceutics International Inc (TSX:I) revealed on Monday the receipt of final approval from the US Food and Drug Administration (FDA) for its dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths for the treatment of attention deficit hyperactivity disorder.
Intellipharmaceutics / Par to Make Immediate Commercial Launch of 15 and 30 mg Generic Focalin XR(R)
GlobeNewswire - Mon Nov 18, 3:34PM CST
- FDA Issues Final Approval of 15 mg, With 180 Days of Exclusivity, and 30 mg; and
IIROC Trading Halt - I
CNW Group - Mon Nov 18, 3:01PM CST
The following issues have been halted by IIROC:
Intellipharmaceutics International Inc completes USD3.1m in public offering
M2 - Thu Aug 01, 6:19AM CDT
Pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) announced on Wednesday the completion of its USD3.1m underwritten public offering.